Immatics N.v. · NASDAQ:IMTX
Immatics — Presidential Symposium III, Proffered Paper #1600O (October 2025)
23 slides from Immatics's conference presentation, Oct 20, 2025
Slide 1: Efficacy and Safety of Anzutresgene Autoleucel (IMA203) in Uveal Melanoma
Efficacy and Safety of Anzutresgene Autoleucel (IMA203), a PRAME - directed T - cell Receptor T - cell Therapy, in Patients with Previously Treated Advanced or Metastatic Uveal Melanoma from a Phase 1 Trial S. P. Patel 1 , A.M. Tsimberidou 2 , J.J. Luke 3 , W. Alsdorf 4 , A. Busse 5 , S. C. DeVane 6
Slide 2: Declaration of Interests
Content of this presentation is copyright and responsibility of the author and the sponsor. Permission is required for re - use. DECLARATION OF INTERESTS Institutional clinical trial support: Linnaeus, Replimune Advisory board, steering committee, data safety monitoring board, consulting: Bristol -
Slide 3: Does targeting a highly expressed antigen in a cold tumour lead to clinical benefit?
In a cold tumour, does targeting a highly expressed antigen with TCR T - cell therapy lead to clinical benefit?
Slide 4: Uveal Melanoma: The Disease
A C B D Chattopadhyay C,… Patel SP. Cancer . 2016. Reproduced with corresponding author permission. Uveal Melanoma: The Disease Posterior uvea Anterior uvea Ciliary body Choroid layer Iris Retina Sclera Vitreous Humor Choroid layer melanoma Ciliary body melanoma Iris melanoma • Most common tumor of
Slide 5: Uveal Melanoma: The Dilemma
Uveal Melanoma: The Dilemma FDA approvals for melanoma rarely demonstrate efficacy in rare subtypes 1995 Interferon α - 2b (Intron A) 1998 Aldesleukin (Proleukin) 2015 Cobimetinib (Cotellic) T - vec (Imlygic) 2018 Encorafenib (Braftovi) Binimetin i b (Mektovi) 2020 Atezolizumab (Tecentriq) Nivolumab
Slide 6: Uveal Melanoma: The Dilemma
Uveal Melanoma: The Dilemma FDA approvals for melanoma rarely demonstrate efficacy in rare subtypes 2015 (Cotellic) 201 4 2018 2020 ( T ecentriq) 2022 T ebentafusp (Kimmtrak) 2013 2024 2023 Melphalan (Hepzato Kit) 2025 Nivolumab + Ipilimumab (Opdivo + Yervoy) Adapted from Citeline Disease Analysis (
Slide 7: PRAME expression and mechanism of action of anzu-cel
% PRAME+ Patients 1 Indication 95% Cutaneous melanoma 95% Uterine carcinoma 95% Uterine carcinosarcoma 95% Synovial sarcoma 90% Uveal melanoma 2 90% Mucosal melanoma 85% Ovarian carcinoma (clear cell, endometroid) 70% Squamous cell NSCLC 65% Triple - negative breast carcinoma 45% Small cell lung can
Slide 8: Phase 1 Study Design: Anzu-cel in Advanced Solid Tumours Expressing PRAME
BID, twice daily; ECOG PS, Eastern Cooperative Oncology Group performance status; FU, follow - up; HLA, human leukocyte antigen; I L, interleukin; IU, international unit; mRNA, messenger ribounucleic acid; QC, quality control; RP2D, recommended phase 2 dose at 1 - 10x10 9 TCR T cells; SUBQ, subcutan
Slide 9: Anzu-cel Phase 1 Study: Patient Disposition
Data cutoff: Sep 24, 2025. a Mucosal melanoma n=2, melanoma of unknown primary n=1; DL, dose level; RP2D, recommended phase 2 dose at 1 - 10x10 9 TCR T cells; cORR, confirmed overall response rate; TCR, T - cell receptor. Total Safety Population (N=74) n=13 non - melanoma n=1 in Phase 1a n=27 starte
Slide 10: Demographics: Uveal Melanoma
N=16 Baseline Characteristic 62 (32, 74) Age, median (range) 10 (63) Female, n (%) 7 (44) Baseline ECOG status 1, n (%) 9 (56) LDH ≥ ULN, n (%) 19 / 75 / 6 AJCC stage* , IV M1a/b/c, % 10 (3, 21) Median target lesion SPD, cm (range) 13 (81) Liver and extrahepatic metastasis , n (%) 2 (13) Liver metas
Slide 11: Treatment-emergent adverse events
n=16 Grade Any 3/4 Grade TEAEs in ≥25% of patients, n (%) 15 (94) 15 (94) Blood and lymphatic system disorders 15 (94) 15 (94) Neutropenia 8 (50) 12 (75) Anemia 6 (38) 9 (56) Thrombocytopenia 6 (38) 6 (38) Leukopenia Lymphopenia 4 (25) 4 (25) 0 (0) 15 (94) Gastrointestinal disorders 0 (0) 13 (81) Na
Slide 12: Anzu-cel: Best Overall Response in Uveal Melanoma
- 18 - 23 - 25 - 38 - 40 - 41 - 42 - 44 - 48 - 51 - 59 - 65 - 78 - 79 - 84 - 100 - 50 0 - 6 50 PD SD PR cPR ongoing Anzu - cel: Best Overall Response in Uveal Melanoma Best % Change in Sum of Longest Diameter of Target Lesions from Baseline and BOR (RECIST 1.1) Confirmed ORR*: 67% (10/15) *all respo
Slide 13: Anzu-cel: Duration of Response in Uveal Melanoma
Months Post T - Cell Infusion Change in Sum of Longest Diameter of TargeLt esi on s fro m B as eli ne (%) BL PR n=16 Anzu - cel: Duration of Response in Uveal Melanoma cPR A - DL5 - 01 A - DL5 - 10 A - DL5 - 19 A - DL5 - 21 A - DL5 - 26 A - DL5 - 32 A - DL4 - 10 A - DL5 - 34 A - DL4 - 09 a A - DL5 -
Slide 14: Anzu-cel: Duration of Response in Uveal Melanoma
Months Post T - Cell Infusion - 50 0 50 Change in Sum of Longest Diameter of Target Lesions from Baseline (%) 0 3 12 6 9 15 BL PR Anzu - cel: Duration of Response in Uveal Melanoma - 100 cPR A - DL5 - 01 A - DL5 - 10 A - DL5 - 19 A - DL5 - 21 A - DL5 - 26 A - DL5 - 32 A - DL4 - 10 A - DL5 - 34 A - D
Slide 15: Anzu-cel: Survival Outcomes in Uveal Melanoma
Anzu - cel: Survival Outcomes in Uveal Melanoma Progression - Free Survival (median follow - up: 10.4 months) Median PFS: 8.5 months (range: 1.4, 32.9) 12 - month PFS: 39% Overall Survival (median follow - up: 14.3 months) Median OS: not reached (range: 4.3+, 34.2+) 12 - month OS: 71% 100 50 PFS (%)
Slide 16: Patient Case: Response After Prior PRAME-directed Treatment
Patient Case: Response After Prior PRAME - directed Treatment A - DL5 - 36 • 44 years of age (female) • Prior lines of treatment = 1 – PRAME - directed treatment – Time on treatment: Oct 2023 - Dec 2024 – BOR: SD/No Response – Anzu - cel infusion: Jan 2025 • Tumor burden – Hepatic - only disease – T
Slide 17: Conclusions
• Anzu - cel tolerability profile: – Most frequent TEAEs: anticipated cytopaenias – CRS was mostly grade 1 - 2 • One - time infusion of anzu - cel in this cohort shows high response rates to immunotherapy for patients with metastatic uveal melanoma: – 67% cORR and 11.0 months mDOR – mPFS: 8.5 months
Slide 18: Targeting PRAME with TCR-specific T cells results in clinical activity
In a cold tumour, targeting a highly expressed antigen (PRAME) with TCR - specific T cells results in clinical activity. These results are being verified in a Phase 2 extension cohort. 18
Slide 19: Thank You – Study Participants & Caregivers
Content of this presentation is copyright and responsibility of the author and the sponsor. Permission is required for re - use. Thank You – Study Participants & Caregivers Anzu - cel Phase 1 Study Sponsor: Immatics University of Colorado Cancer Center Aurora, CO, USA (current) University of Texas M
Slide 20: Supplemental Data
Supplemental Data Content of this presentation is copyright and responsibility of the author and the sponsor. Permission is required for re - use. 20
Slide 21: Anzu-cel in UM: Responses of Metastatic Lesions
Anzu - cel in UM: Responses of Metastatic Lesions Median shrinkage Content of this presentation is copyright and responsibility of the author and the sponsor. Permission is required for re - use. 21 - 49.6% (n=26) - 28.6% (n=3) - 51.6% (n=6) - 76.7% (n=6) - 46.2% (n=11 a ) Data cut - off Sep 24, 202
Slide 22: Patients with Uveal Melanoma Treated with Anzu-cel in Phase 1b
Content of this presentation is copyright and responsibility of the author and the sponsor. Permission is required for re - use. Reason for Comment BOR (Max % change of BOR Total infused dose TCR - T cells 1 Prior local liver - directed treatments Prior treatments No of prior treatment rget lesions)
Slide 23: Patients with Uveal Melanoma Treated with Anzu-cel in Phase 1b Dose Expansion
Patients with Uveal Melanoma Treated with Anzu - cel in Phase 1b Dose Expansion (n=16) - 37.5 Progressive disease at 1.4 months Non - target lesion PFS progression PD 3.71 Tebentafusp Ipilimumab + Nivolumab A - DL5 - 35 Uveal 2 Melanoma - 6.3 Progressive disease at 1.4 months New lesion PFS PD 2.56
Immatics — Presidential Symposium III, Proffered Paper #1600O (October 2025) on 6ix